Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE
Ultragenyx Pharmaceutical stock price today
$29.9
-13.52
-31.14%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 13 hours
Ultragenyx Pharmaceutical stock price monthly change
-3.81%
month
Ultragenyx Pharmaceutical stock price quarterly change
-3.81%
quarter
Ultragenyx Pharmaceutical stock price yearly change
-11.73%
year
Ultragenyx Pharmaceutical key metrics
Market Cap | 4.03B |
Enterprise value | 2.58B |
P/E | -3.88 |
EV/Sales | 7.11 |
EV/EBITDA | -4.03 |
Price/Sales | 7.39 |
Price/Book | 7.62 |
PEG ratio | 0.07 |
EPS | -8.03 |
Revenue | 442.58M |
EBITDA | -538.27M |
Income | -613.35M |
Revenue Q/Q | 8.29% |
Revenue Y/Y | 15.28% |
Profit margin | -194.71% |
Oper. margin | -178.6% |
Gross margin | 92.21% |
EBIT margin | -178.6% |
EBITDA margin | -121.62% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeUltragenyx Pharmaceutical stock price history
Ultragenyx Pharmaceutical stock forecast
Ultragenyx Pharmaceutical financial statements
Average Price Target
$90
Potential upside: 201.00%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 108.30M | -159.82M | -147.57% |
|---|---|---|---|
| Sep 2023 | 98.05M | -159.64M | -162.82% |
| Dec 2023 | 127.39M | -123.19M | -96.7% |
| Mar 2024 | 108.83M | -170.68M | -156.83% |
| 2023-08-03 | -2.07 | -2.26 |
|---|
| Jun 2023 | 1311310000 | 1.18B | 90.16% |
|---|---|---|---|
| Sep 2023 | 1238140000 | 1.20B | 97.44% |
| Dec 2023 | 1491013000 | 1.21B | 81.53% |
| Mar 2024 | 1307080000 | 1.16B | 89.27% |
| Jun 2023 | -116.16M | 99.41M | 33.02M |
|---|---|---|---|
| Sep 2023 | -117.87M | 64.29M | 25.23M |
| Dec 2023 | -83.90M | -107.01M | 330.61M |
| Mar 2024 | -190.72M | 94.43M | -58K |
Ultragenyx Pharmaceutical alternative data
| Aug 2023 | 1,311 |
|---|---|
| Sep 2023 | 1,311 |
| Oct 2023 | 1,311 |
| Nov 2023 | 1,311 |
| Dec 2023 | 1,311 |
| Jan 2024 | 1,311 |
| Feb 2024 | 1,311 |
| Mar 2024 | 1,276 |
| Apr 2024 | 1,276 |
| May 2024 | 1,276 |
| Jun 2024 | 1,276 |
| Jul 2024 | 1,276 |
Ultragenyx Pharmaceutical other data
90.08%
-8.34%
of RARE is owned by hedge funds
204
-7
61.14M
-5.65M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2024 | 0 | 30000 |
| Mar 2024 | 0 | 38991 |
| Apr 2024 | 0 | 142 |
| May 2024 | 0 | 354 |
| Jun 2024 | 0 | 11543 |
| Jul 2024 | 0 | 584 |
| Dec 2024 | 0 | 8273 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | KAKKIS EMIL D director, officer.. | Common Stock | 8,273 | $50 | $413,650 | ||
Sale | SANDERS CORAZON (CORSEE) D. director | Common Stock | 584 | $40.98 | $23,932 | ||
Sale | PARSCHAUER KARAH HERDMAN officer: EVP and Chief Legal Of.. | Common Stock | 9,806 | $45 | $441,270 | ||
Sale | SANDERS CORAZON (CORSEE) D. director | Common Stock | 1,737 | $41.1 | $71,391 | ||
Sale | CROMBEZ ERIC officer: EVP and Chief Medical .. | Common Stock | 354 | $43.66 | $15,456 | ||
Sale | CROMBEZ ERIC officer: EVP and Chief Medical .. | Common Stock | 142 | $44.1 | $6,262 | ||
Sale | KASSBERG THOMAS RICHARD officer: CBO & EVP | Common Stock | 11,509 | $49.93 | $574,644 | ||
Sale | FUST MATTHEW K director | Common Stock | 2,550 | $50.89 | $129,770 | ||
Sale | FUST MATTHEW K director | Common Stock | 2,145 | $50.85 | $109,073 | ||
Sale | FUST MATTHEW K director | Common Stock | 7,500 | $50.88 | $381,600 |
| Patent |
|---|
Application Filling date: 28 Mar 2022 Issue date: 21 Jul 2022 |
Application Filling date: 22 May 2020 Issue date: 14 Jul 2022 |
Application Filling date: 11 Nov 2021 Issue date: 30 Jun 2022 |
Grant Filling date: 3 Dec 2018 Issue date: 17 May 2022 |
Application Filling date: 12 Nov 2021 Issue date: 5 May 2022 |
Application Filling date: 3 Jan 2020 Issue date: 24 Mar 2022 |
Application Filling date: 23 Apr 2021 Issue date: 10 Mar 2022 |
Application Filling date: 18 Dec 2019 Issue date: 20 Jan 2022 |
Grant Filling date: 26 Mar 2020 Issue date: 21 Dec 2021 |
Application Filling date: 1 Oct 2019 Issue date: 16 Sep 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2024 2 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 15 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 2 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 3 Aug 2023 | Q2 2023 Earnings Call Transcript |
Mereo BioPharma: Buy Rating Despite No Early Study Completion Of Setrusumab For OI
Abeona Therapeutics: pz-cel Has Massive Potential For RDEB Patients
Ultragenyx: Commercial Engine Fuels Rare Disease Pipeline
Abeona Therapeutics: Despite Some Competitive Pressure, This Looks Undervalued
Abeona: BLA Resubmission Of Pz-Cel Gets Ball Rolling Towards Other Milestones
Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching
Kyowa Kirin: High-Risk High-Return Call Reiterating Our Buy Rating
Ultragenyx: A Promising Bet On Rare Genetic Disorder Therapies
Ultragenyx: Despite OI Trial Doubts, This Is A Robust Rare Disease Company
-
What's the price of Ultragenyx Pharmaceutical stock today?
One share of Ultragenyx Pharmaceutical stock can currently be purchased for approximately $29.9.
-
When is Ultragenyx Pharmaceutical's next earnings date?
Unfortunately, Ultragenyx Pharmaceutical's (RARE) next earnings date is currently unknown.
-
Does Ultragenyx Pharmaceutical pay dividends?
No, Ultragenyx Pharmaceutical does not pay dividends.
-
How much money does Ultragenyx Pharmaceutical make?
Ultragenyx Pharmaceutical has a market capitalization of 4.03B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 19.52% to 434.25M US dollars. Ultragenyx Pharmaceutical made a loss 606.64M US dollars in net income (profit) last year or -$2.26 on an earnings per share basis.
-
What is Ultragenyx Pharmaceutical's stock symbol?
Ultragenyx Pharmaceutical Inc. is traded on the NASDAQ under the ticker symbol "RARE".
-
What is Ultragenyx Pharmaceutical's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Ultragenyx Pharmaceutical?
Shares of Ultragenyx Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Ultragenyx Pharmaceutical's key executives?
Ultragenyx Pharmaceutical's management team includes the following people:
- Dr. Emil D. Kakkis M.D., Ph.D. Pres, Chief Executive Officer & Director(age: 65, pay: $1,430,000)
- Dr. Camille L. Bedrosian M.D. Chief Medical Officer & Executive Vice President(age: 72, pay: $844,420)
- Mr. Erik Harris Executive Vice President & Chief Commercial Officer(age: 55, pay: $793,860)
- Mr. John Richard Pinion II Chief Quality Operations Officer & Executive Vice President of Translational Sciences(age: 59, pay: $747,200)
- Ms. Mardi C. Dier Executive Vice President & Chief Financial Officer(age: 61, pay: $216,350)
-
How many employees does Ultragenyx Pharmaceutical have?
As Jul 2024, Ultragenyx Pharmaceutical employs 1,276 workers.
-
When Ultragenyx Pharmaceutical went public?
Ultragenyx Pharmaceutical Inc. is publicly traded company for more then 11 years since IPO on 31 Jan 2014.
-
What is Ultragenyx Pharmaceutical's official website?
The official website for Ultragenyx Pharmaceutical is ultragenyx.com.
-
Where are Ultragenyx Pharmaceutical's headquarters?
Ultragenyx Pharmaceutical is headquartered at 60 Leveroni Court, Novato, CA.
-
How can i contact Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato, CA and company can be reached via phone at +41 54838800.
-
What is Ultragenyx Pharmaceutical stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for Ultragenyx Pharmaceutical in the last 12 months, the avarage price target is $90. The average price target represents a 201.00% change from the last price of $29.9.
Ultragenyx Pharmaceutical company profile:
Ultragenyx Pharmaceutical Inc.
ultragenyx.comExchange:
NASDAQ
Full time employees:
1,276
Industry:
Biotechnology
Sector:
Healthcare
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
60 Leveroni Court
Novato, CA 94949
Novato, CA 94949
CIK: 0001515673
ISIN: US90400D1081
CUSIP: 90400D108
